title: [Correlation of hormone-metabolic status in breast cancer and effectiveness of adjuvant hormone therapy].
abstract: Hormono-metabolic status was assayed before and after month 6, 12, 24, 36, 48, 54 and 60 of therapy in 72 patients with receptor-positive tumors of the breast who completed 5 years of adjuvant tamoxifen (20 mg/24 hrs) or letrozole (2.5 mg/24 hrs). Eleven patients were not followed up, 11 relapsed and had metastases while 50 completed therapy. Significant fall in body mass (Ketle's index), in C-peptide concentration after an insignificant rise and C-peptide/insulin ratio 129 min after glucose loading, low basal blood level of estradiol as well as stable estradiolemia throughout treatment were characteristic of cases of pre-treatment recurrence and metastastic spread. Insulin resistance status, basal serum-estradiol level and fasting its course of development during hormonotherapy should be the subject of further research in criteria for adjuvant hormonotherapy efficacy.
authors.forename: V G
authors.initials: VG
authors.lastname: Ivanov
authors.forename: E V
authors.initials: EV
authors.lastname: Tsyrlina
authors.forename: I G
authors.initials: IG
authors.lastname: Kovalenko
authors.forename: T E
authors.initials: TE
authors.lastname: Poroshina
authors.forename: V B
authors.initials: VB
authors.lastname: Gamaiunova
authors.forename: S A
authors.initials: SA
authors.lastname: Malysheva
authors.forename: E K
authors.initials: EK
authors.lastname: Zhil'tsova
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Barash
authors.forename: E B
authors.initials: EB
authors.lastname: Shcherbakova
authors.forename: V F
authors.initials: VF
authors.lastname: Semiglazov
authors.forename: L M
authors.initials: LM
authors.lastname: Bershteĭn
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy*; D002096:C-Peptide / Q000097:blood; D017024:Chemotherapy, Adjuvant; D004958:Estradiol / Q000097:blood*; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D000077289:Letrozole; D008875:Middle Aged; D009570:Nitriles / Q000008:administration & dosage; D011960:Receptors, Estrogen / Q000097:blood*; D011980:Receptors, Progesterone / Q000097:blood; D013629:Tamoxifen / Q000008:administration & dosage; D013997:Time Factors; D014230:Triazoles / Q000008:administration & dosage
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D002096:C-Peptide; D007328:Insulin; D009570:Nitriles; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D014230:Triazoles; D013629:Tamoxifen; D004958:Estradiol; D000077289:Letrozole